2007
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. Journal Of Clinical Oncology 2007, 25: 4414-4422. PMID: 17785706, DOI: 10.1200/jco.2007.10.6823.Peer-Reviewed Original ResearchConceptsDistant relapse-free survivalResidual cancer burdenHormone receptor statusNeoadjuvant chemotherapyHormone therapyPathologic responseReceptor statusCancer burdenResidual diseasePathologic American Joint CommitteeMultivariate Cox regression analysisAdjuvant hormone therapyBreast cancer burdenDifferent treatment cohortsPretreatment clinical stageAmerican Joint CommitteeCox regression analysisRelapse-free survivalSequential paclitaxelDistant relapseSame prognosisComplete responseNodal metastasisTreatment cohortsClinical stage
2006
Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)?
Katz A, Saad E, Pusztai L. Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)? Journal Of Clinical Oncology 2006, 24: 10541-10541. DOI: 10.1200/jco.2006.24.18_suppl.10541.Peer-Reviewed Original ResearchInvasive lobular carcinomaHormone therapyILC patientsRandomized trialsInvasive ductal carcinomaNA chemotherapyBreast cancerNA therapyPCR rateRetrospective seriesEstrogen receptorPhase III randomized trialsPathologic response rateRole of chemotherapyIndependent predictive factorsOngoing randomized trialsEarly breast cancerFuture randomized trialsInvasive breast cancerDistinct clinical behaviorPotential therapeutic implicationsAdjuvant trialsCT regimensPossible overtreatmentIDC patients